NMUS - Nemus Bioscience, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.425
-0.105 (-19.81%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.530
Open0.000
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.000 - 0.000
52 Week Range
Volume0
Avg. Volume325,144
Market Cap56.714M
Beta (3Y Monthly)1.27
PE Ratio (TTM)N/A
EPS (TTM)-0.179
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.48
Trade prices are not sourced from all markets
  • GlobeNewswire8 days ago

    Nemus Bioscience to Present at BIO Investor Forum

    LONG BEACH, CA, Oct. 15, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc. (NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today that Dr. Brian Murphy, Chief Executive Officer and Chief Medical Officer,  will be presenting at the BIO Investor Forum in San Francisco, CA. The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies.

  • GlobeNewswire15 days ago

    Nemus Bioscience Announces that Emerald Health Sciences has Provided a Credit Facility of up to $20 Million and Adopted an Open Market Share Purchase Program of up to 10 Million Common Shares

    LONG BEACH, CA, Oct. 08, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc. (NMUS), focused on the development of bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that the Company’s majority shareholder, Emerald Health Sciences, Inc. (EHS), will provide the Company with a credit facility of up to $20 million for operating purposes and has committed to purchase up to 10 million shares of Nemus common stock in the open market. The Board of Directors of Nemus also appointed Dr. Avtar Dhillon, MD, as Executive Chairman of the Board effective October 8, 2018.

  • GlobeNewswire27 days ago

    NEMUS Bioscience to Present at The MicroCap Conference

    LONG BEACH, CA, Sept. 26, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - NEMUS Bioscience, Inc. (NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today that Dr. Brian Murphy, Chief Executive Officer and Chief Medical Officer,  will be presenting at The MicroCap Conference in New York City.

  • GlobeNewswire2 months ago

    NEMUS Bioscience to Present at the Rodman & Renshaw 20th Annual Global Investment Conference

    Long Beach, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- NEMUS Bioscience, Inc. (NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today that Dr. Brian Murphy, CEO and Chief Medical Officer, will present at the Rodman & Renshaw 20th Annual Global Investment Conference taking place at the St. Regis Hotel in New York, NY. To view the live webcast, please access the following link at the time of the presentation: http://wsw.com/webcast/rrshq28/nmus/.  An archived version of the webcast will be available for 90 days in the investor section of the Nemus Bioscience website. This press release contains forward-looking statements, including statements about product development, business strategy and milestones, and the studies relating to and the potential benefits of Nemus’ proprietary, cannabinoid-based therapeutics.

  • GlobeNewswire3 months ago

    UPDATE: Nemus Bioscience, Inc. Signs Agreement with Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredient for Glaucoma

    Nemus Bioscience, Inc. (NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced an agreement with Albany Molecular Research Inc. The agreement will capitalize on AMRI's process chemistry expertise in the synthesis and formulation of Nemus' proprietary prodrug of tetrahydrocannabinol (THC). This molecule forms the basis of NB1111, Nemus' compound in development for the treatment of glaucoma.

  • GlobeNewswire3 months ago

    Nemus Bioscience, Inc. Signs Agreement with Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredient for Glaucoma

    Nemus Bioscience, Inc. (NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced an agreement with Albany Molecular Research Inc. The agreement will capitalize on AMRI's process chemistry expertise in the synthesis and formulation of Nemus' proprietary prodrug of tetrahydrocannabinol (THC). This molecule forms the basis of NB1111, Nemus' compound in development for the treatment of glaucoma.

  • ACCESSWIRE3 months ago

    Nemus Bioscience Discusses Pre-Clinical Developments and Target Indications in New SNNLive Video Interview with StockNewsNow.com

    LOS ANGELES, CA / ACCESSWIRE / July 16, 2018 / StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Dr. Brian Murphy, MD, MPH, MBA, CEO/CMO of NEMUS Bioscience, ...

  • Marketwired11 months ago

    Nemus Bioscience Files Arbitration Petition Against Schneider Finance, LLC and SB Securities, Ltd. for Failure to Close $20 Million Financing and Failure to Honor Guarantee

    NEMUS Bioscience, Inc. today announced that it has submitted a demand commencing arbitration against Schneider Finance, LLC and SB Securities, Ltd., both affiliates of Schneider Brothers Ltd., as well ...